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The Akt kinase signals directly to endothelial nitric oxide
synthase
B.J. Michell*, J.E. Griffiths†, K.I. Mitchelhill*, I. Rodriguez-Crespo‡, T. Tiganis*,
S. Bozinovski†, P.R. Ortiz de Montellano‡, B.E. Kemp* and R.B. Pearson†
Endothelial nitric oxide synthase (eNOS) is an
important modulator of angiogenesis and vascular tone
[1]. It is stimulated by treatment of endothelial cells in a
phosphatidylinositol 3-kinase (PI 3-kinase)-dependent
fashion by insulin-like growth factor-1 (IGF-1) and
vascular endothelial growth factor (VEGF) [2,3] and is
activated by phosphorylation at Ser1177 in the
sequence RIRTQS1177F (in the single-letter amino acid
code) [4]. The protein kinase Akt is an important
downstream target of PI 3-kinase [5,6], regulating
VEGF-stimulated endothelial cell survival [7]. Akt
phosphorylates substrates within a defined motif [8],
which is present in the sequence surrounding Ser1177
in eNOS. Both Akt [5,6] and eNOS [9] are localized to,
and activated at, the plasma membrane. We found that
purified Akt phosphorylated cardiac eNOS at Ser1177,
resulting in activation of eNOS. Phosphorylation at this
site was stimulated by treatment of bovine aortic endo-
thelial cells (BAECs) with VEGF or IGF-1, and Akt was
activated in parallel. Preincubation with wortmannin, an
inhibitor of Akt signalling, reduced VEGF- or
IGF-1-induced Akt activity and eNOS phosphorylation.
Akt was detected in immunoprecipitates of eNOS from
BAECs, and eNOS in immunoprecipitates of Akt,
indicating that the two enzymes associate in vivo. It is
thus apparent that Akt directly activates eNOS in
endothelial cells. These results strongly suggest that
Akt has an important role in the regulation of normal
angiogenesis and raise the possibility that the
enhanced activity of this kinase that occurs in
carcinomas may contribute to tumor vascularization
and survival.
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Results and discussion
Angiogenesis is impaired in eNOS knockout mice follow-
ing ischemic challenge and is not restored by VEGF treat-
ment, indicating that eNOS lies downstream of VEGF [1].
Release of NO stimulated by treatment of endothelial
cells with VEGF or IGF-1 is approximately halved by the
PI 3-kinase inhibitors wortmannin and LY2940002 [2,3],
but the mechanism of PI 3-kinase-mediated activation of
eNOS has not been characterized. We previously observed
that the AMP-activated protein kinase (AMPK) catalyzes
phosphorylation of eNOS on Ser1177 resulting in activa-
tion of the enzyme [4]. The sequence surrounding
Ser1177 closely resembles the consensus Akt substrate-
recognition motif identified using synthetic peptides
Arg-X-Arg-Z-Z-Ser/Thr-Hyd (where X is any amino acid,
Z is a small residue other than glycine and Hyd is a bulky
hydrophobic residue) [8]. This raises the possibility that
Akt may directly phosphorylate and activate eNOS. We
found that recombinant eNOS, co-expressed in bacteria
with calmodulin (CaM) to maintain its stability, was
readily phosphorylated by purified Akt conjugated to glu-
tathione-S-transferase (GST–Akt), as was partially purified
rat heart eNOS (Figure 1a). Rat heart eNOS was used for
all subsequent experiments because it is myristoylated and
palmitoylated [4] and therefore localized to the plasma
membrane. This form of eNOS contains some associated
CaM and thus Akt catalyzes a low level of eNOS phospho-
rylation, which is significantly reduced by removal of CaM
with EGTA and stimulated more than 10-fold by the addi-
tion of Ca2+–CaM (Figure 1a, lower panel and 1b). Binding
of Ca2+–CaM to eNOS has been proposed to induce a con-
formational change in eNOS, allowing phosphorylation at
Ser1177 [4]. Under these conditions, the stoichiometry of
phosphorylation was estimated to be approximately 50%,
from Coomassie blue staining of the eNOS preparation fol-
lowing SDS–PAGE (data not shown).
In parallel, eNOS was phosphorylated by AMPK in the
absence of Ca2+–CaM, a condition that favours phosphory-
lation at an inhibitory site, Thr495, as well as at Ser1177
[4]. Immunoblotting with a phospho-Ser1177-specific anti-
body revealed that both kinases catalyzed phosphorylation
at this site (Figure 1b). To further characterize the speci-
ficity of these reactions, the phosphorylated eNOS was
analyzed by two-dimensional tryptic phosphopeptide
mapping (Figure 1c–e). AMPK phosphorylated eNOS at
Ser1177 and Thr495, as previously described [4]. Phospho-
rylation by Akt was largely confined to Ser1177, as shown
by comparison of the phosphopeptide maps following
phosphorylation by the two kinases (Figure 1c,e). This
determination was confirmed by phosphate-release analy-
sis, which showed phosphorylation at cycle 3 during
amino-terminal Edman degradation of the peptide
TQS*FSLQER (data not shown). In the absence of
Ca2+–CaM, Akt-mediated phosphorylation of Ser1177 pro-
ceeded at a significantly slower rate and no Thr495 phos-
phorylation was observed (data not shown).
Akt phosphorylates and activates eNOS, rendering the
enzyme 40% more sensitive to CaM (changing the relative
K0.5, the concentration of added CaM required for half-
maximal enzyme activity read from the dose-response
curves, from 135 to 85 nM) and increasing the maximum
activity (Vmax) by 50% (Figure 2). Immunoblotting con-
firmed that this activation was associated with phosphoryla-
tion of Ser1177. Phosphorylation at this site complemented
and enhanced the regulation of eNOS by Ca2+–CaM, allow-
ing increased NO production at lower intracellular Ca2+
concentrations. We have proposed previously that this was
due to phosphorylation-induced relief of an autoinhibitory
function of the carboxyl terminus of eNOS [4]; supporting
this hypothesis, truncation mutagenesis at Ser1177 renders
eNOS constitutively active (B.J.M., I.R-C., P.R. O. de M.
and B.E.K., unpublished observations).
To assess the relationship between Akt and phosphoryla-
tion of eNOS in vivo, we examined extracts from BAECs
treated with VEGF or IGF-1 with and without pretreatment
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Phosphorylation of eNOS by Akt and AMPK. The active GST–Akt
fusion protein was purified by glutathione–Sepharose chromatography
of extracts from transiently transfected HEK 293 cells [17] treated with
100 µM pervanadate as described previously for fibroblasts [18].
AMPK and recombinant and rat heart eNOS were purified as
described previously [4,19]. Phosphorylation of eNOS (30 nM) was
carried out in the presence or absence of GST–Akt (Akt), AMPK,
100 µM CaCl2 with 500 nM CaM and/or 1 mM EGTA as indicated, in
the presence of kinase assay buffer (50 mM Hepes, pH 7.5, 10 mM
MgCl2, 5% glycerol, 1 mM DTT, 0.05% Triton X-100) containing
20 µM [γ-32P] ATP (10,000 cpm/pmol). After a 30 min incubation at
22°C, the reactions were stopped with SDS–PAGE sample buffer and
subjected to SDS–PAGE on a 10% slab gel. (a,b) Proteins were
transferred onto a polyvinyl difluoride (PVDF) membrane.
Phosphorylated eNOS (32P) was visualized by Phosphorimage analysis
and the phosphorylation at Ser1177 and total eNOS were detected by
immunoblot analysis. To detect phosphorylation of Ser1177, blots
were probed with anti-phospho-eNOS antibodies directed to
RIRTQSpFSLQER (Ser1177) [4]. The top and middle panels in (a)
refer to the recombinant eNOS and are labeled at the top of the figure.
The control lane is phosphorylated in the absence of added CaM or
Akt. The other panels in (a,b) refer to rat heart eNOS. (c–e) eNOS gel
bands from duplicate reactions were excised and digested with
trypsin. Phosphopeptides were isolated from in-gel tryptic digests and
phosphopeptide mapped as described previously [20].
Figure 2
Effect of Akt-catalyzed phosphorylation on eNOS activity.
Phosphorylation assays were performed in kinase assay buffer in the
presence of 200 µM ATP, 2 µM CaCl2 and 500 nM CaM with or
without Akt. After phosphorylation, eNOS was diluted 1:100 and the
change in eNOS activity was determined by monitoring the eNOS-
catalyzed conversion of L-[3H]-arginine to L-[3H]-citrulline as a function
of the CaM concentration [4]. The inset shows the relative amounts of
eNOS phosphorylated at Ser1177, determined by immunoblot
analysis. Blots were probed with anti-phospho-Ser1177 antibody and
then stripped and reprobed for total eNOS to adjust for variations in
protein recovery and gel loading. Re-plotting of this data with eNOS
activity expressed as a percentage of the maximum achieved in either
the presence or the absence of Akt also revealed that phosphorylation
enhances eNOS sensitivity to CaM (see Supplementary material).
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with the PI-3-kinase inhibitor wortmannin (Figure 3a,b).
Akt was stimulated by each growth factor and this activation
was strongly inhibited by wortmannin. Concomitant phos-
phorylation of eNOS at Ser1179  (equivalent to Ser1177 in
rat eNOS) was seen in each case but, in keeping with previ-
ous data, this phosphorylation was only partially 
wortmannin sensitive. The eNOS and Akt proteins co-
immunoprecipitated from both starved and serum-supple-
mented BAECs (Figure 3c), indicating a direct interaction
of the two enzymes in vivo. Treatment of BAECs with
rapamycin, a specific inhibitor of p70 S6 kinase, the other
major downstream target of PI 3-kinase, had no effect on
IGF-1-induced phosphorylation of eNOS at Ser1179 (see
Supplementary material). It is not possible to rule out some
involvement of two other PI 3-kinase effectors, serum and
glucocorticoid-inducible kinase (SGK) and the atypical
protein kinase Cs (PKCs), although stimulation of PKCζ
with phorbol ester does not result in phosphorylation of
Ser1179 (B.J.M. and B.E.K., unpublished observations).
We anticipated that there would be PI-3-kinase-inde-
pendent pathways capable of activating eNOS because
of the partial wortmannin insensitivity of Ser1179 phos-
phorylation. It is likely that these pathways will, at least
in part, involve signaling via Ca2+–CaM. Ca2+–CaM-
dependent eNOS activity and phosphorylation is
detected in the absence of added kinase (Figure 2 and
data not shown) and eNOS is activated by treatment of
endothelial cells with the calcium ionophore ionomycin
and inactivated by Ca2+ chelation and/or calmodulin
antagonism [3]. Furthermore, the motif surrounding
Ser1179 contains the Arg-X-X-Ser-Hyd sequence motif
favored by CaM-dependent protein kinase II (CaMK-II;
[10]). Interestingly, although IGF-1 is a more potent acti-
vator of Akt, VEGF promotes greater phosphorylation of
eNOS on Ser1179. One interpretation of these data is
that VEGF signals more strongly than IGF-1 by an alter-
native pathway, perhaps by increasing intracellular Ca2+
through the activation of phospholipase Cγ [11].
We have shown that Akt phosphorylates and activates
eNOS, indicating that Akt has an important role in the
regulation of angiogenesis and maintenance of vascular
tone [1,9]. Note that, during the revision stage of this
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Regulation of Akt activity and phosphorylation of eNOS in endothelial
cells. BAECs were maintained in culture in Dulbecco’s modified
Eagle’s medium (DME) supplemented with 10% fetal bovine serum
(FBS). Cells were serum-starved in DME containing 0.1% FBS for 20 h
before experimental treatment (control cells). BAECs were incubated
with 50 ng/ml VEGF for 5 min or 50 ng/ml IGF-1 for 15 min, with or
without 200 nM wortmannin pretreatment for 30 min, as indicated. The
different times of treatment with VEGF and IGF-1 were chosen from
time-course experiments of eNOS activation (see Supplementary
material). After experimental treatment, BAECs were washed twice with
PBS pH 7.4, harvested on ice in 0.8 ml lysis buffer containing 20 mM
Hepes, pH 7.4, 2 mM EDTA, 50 mM NaF, 5 mM Na pyrophosphate,
1 mM dithiothreitol (DTT), 2 µg/ml aprotinin, 2 µg/ml leupeptin,
10 µg/ml soya bean trypsin inhibitor, 1 mM phenylmethylsulfonyl
fluoride (PMSF) and 1% (w/v) NP40 and frozen in liquid nitrogen.
Thawed lysates were then clarified by centrifugation at 20,000 × g for
5 min at 4°C. (a) Endogenous Akt activity was assayed using the
specific peptide substrate RPRAATF [8]. Lysate (5 µl) was incubated
for 10 min at 30°C in 25 mM Tris pH 7.5, 0.5 mM DTT, 0.5 mM
benzamidine, 50 µM [γ-32P]ATP (10,000 cpm/pmol), 10 mM MgCl2,
150 µM peptide substrate. The incubation was terminated by addition
of trichloroacetic acid to 10% (w/v). Following 20 min on ice
precipitated protein was pelleted by centrifugation for 20 min at
13,000 × g. The supernatant containing substrate peptide was spotted
onto P81 paper and radioactive inorganic phosphate (32Pi)
incorporated into peptide was quantitated as described previously [18].
The units of activity are pmol Pi transferred per minute per mg protein.
These results were confirmed by immunoblotting with Akt-phospho-
Ser473-specific antibody (New England Biolabs) following
SDS–PAGE of 20 µg of the relevant lysates on a 10% slab gel (inset).
Phosphorylation at this site reflects the activity state of the enzyme
[14]. (b) The eNOS was isolated from extracts by ADP–Sepharose
chromatography. The extracts were mixed with 50 µl ADP–Sepharose
resin for 1–2 h and the beads were washed in 50 mM Tris-HCl, pH 7.5,
1 mM DTT, 10% glycerol, 0.1% Triton X-100. The relative amounts of
phosphorylated Ser1179 were determined by immunoblot analysis as
described in Figure 2 and expressed as mean± standard error (n = 4).
(c) BAECs either maintained in 10% FBS or serum-starved in DME
containing 0.1% FBS for 20 h were harvested as above. Extracts of
one 10 cm plate of 60% confluent cells were immunoprecipitated with
antisera raised to the carboxy-terminal 16 residues of Akt or with the
anti-eNOS monoclonal antibody 1030–1209 (Transduction
Laboratories). Immunoprecipitates (IP) of either Akt or eNOS were
washed extensively in PBS containing 2% Triton X-100, subjected to
SDS–PAGE on a 10% slab gel and immunoblotted with the reciprocal
antibody as indicated (blot). Ig indicates immunoglobulin.
manuscript, two other groups have shown direct activa-
tion of eNOS by Akt [12,13]. This role is distinct from its
well-documented roles in glucose metabolism involving
phosphorylation of glycogen synthase kinase 3 [14] and
cell survival and apoptosis involving phosphorylation of
Bad, procaspase 9 and a forkhead transcription factor
[15,16]. The deregulation of the Akt pathway, especially
through defects in the tumor suppressor PTEN, is impli-
cated in the generation of many human cancers [15].
Thus, in addition to disrupting cell-death pathways,
tumor cells may exploit the activation of Akt to enhance
vascularization and tumor survival. It is significant that
the AMP-activated protein kinase, which senses meta-
bolic stress, also activates eNOS by phosphorylation at
Ser1177/1179. Tumors experience metabolic stress,
which also promotes neovascularization. It is apparent
that Ser1177/1179 in eNOS is a major intersection point
of regulatory pathways for growth factors, metabolic stress
and calcium (Figure 4).
Supplementary material
Supplementary material including a graph of Ser1179 phosphorylation
in BAECs and a time course of eNOS activation is available at
http://current-biology.com/supmat/supmatin.htm.
Acknowledgements
This work was supported by grants from the National Heart Foundation and
NHMRC. B.E.K. is an NHMRC Fellow and R.B.P is supported by a grant
from the Anti-Cancer Council of Victoria. We thank Phillip Cohen for point-
ing out that Ser1177 was located in a potential Akt substrate-specificity
motif on the occasion of his 1997 Pehr Edman lecture. We also thank Frosa
Katsis for generating anti-phospho-eNOS antibodies.
References
1. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et
al.: Nitric oxide synthase modulates angiogenesis in response to
ischemia. J Clin Invest 1998, 101:2567-2578.
2. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is
inhibited by wortmannin. J Clin Invest 1996, 98:894-898.
3. Papapetropolous A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric
oxide production contributes to the angiogenic properties of
vascular endothelial growth factor in human endothelial cells.
J Clin Invest 1997, 100:3131-3139.
4. Chen Z-P, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I,
Witters LA, et al.: AMP-activated protein kinase phosphorylation of
endothelial NO synthase. FEBS Lett 1999, 443:285-289.
5. Alessi DR, Cohen P: Mechanisms of activation and function of
protein kinase B. Curr Opin Genet Dev 1998, 8:55-62.
6. Downward J: Mechanisms and consequences of activation of
protein kinase B/Akt. Curr Opin Cell Biol 1998, 10:262-267.
7. Gerber H-P, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, et al.:
Vascular endothelial growth factor regulates endothelial cell
survival through the phosphatidylinositol 3′-kinase/Akt signal
transduction pathway. J Biol Chem 1998, 273:30336-30343.
8. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P:
Molecular basis for the substrate specificity of protein kinase B:
comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett
1996, 399:333-338.
9. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC: Targeting
of nitric oxide synthase to endothelial cell caveolae via
palmitoylation: implications for nitric oxide signaling. Proc Natl
Acad Sci USA 1996, 93:6448-6453.
10. Kemp BE, Pearson RB: Protein kinase recognition sequence
motifs. Trends Biochem Sci 1990, 15:342-346.
11. Wu HM, Yuan Y, Zawieja DC, Tinsley J, Granger HJ: Role of
phospholipase C, protein kinase C, and calcium in VEGF-induced
venular hyperpermeability. Am J Physiol 1999 276:H535-H542.
12. Fulton D, Gratton J-P, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke
TF, Papapetropoulos A, Sessa WC: Regulation of endothelium-
derived nitric oxide production by the protein kinase Akt. Nature
1999, 399:597-601.
13. Dimmeler S, Fleming I, Fissthaler B, Hermann C, Busse R, Zeiher AM:
Activation of nitric oxide synthase in endothelial cells by Akt-
dependent phosphorylation. Nature 1999, 399:601-605.
14. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P,
et al.: Mechanism of activation of protein kinase B by insulin and
IGF-1. EMBO J 1996, 15:6541-6551.
15. Cantley LC, Neel BG: New insights into tumor suppression: PTEN
suppresses tumor formation by restraining the phosphoinositide
3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999,
96:4240-4245.
16. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al.: Akt
promotes cell survival by phosphorylating and inhibiting a
forkhead transcription factor. Cell 1999, 96:857-868.
17. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese
CB, et al.: Characterisation of a 3-phosphoinositide-dependent
protein kinase which phosphorylates and activates protein kinase
Bα. Curr Biol 1997, 7:261-269.
18. Marmy-Conus NJ, Hemmings BA, Pearson RB: Differential
regulation by calcium reveals distinct signaling requirements for
the activation of Akt and p70s6k. J Biol Chem 1998,
273:4776-4782. 
19. Michell BJ, Stapleton D, Mitchelhill KI, House CM, Katsis F, Witters
LA, et al.: Isoform-specific purification and substrate specificity of
the 5′-AMP-activated protein kinase. J Biol Chem 1996,
271:28445-28450.
20. Mitchelhill KI, Kemp BE: Phosphorylation site analysis by mass
spectrometry. In Protein Phosphorylation. A Practical Approach, vol
2, 2nd edn. Edited by Hardie DG. Oxford: Oxford University
Press, 1999.
21. Matsubara M, Titani K, Taniguchi H: Interaction of calmodulin-
binding domain peptides of nitric oxide synthase with membrane
phospholipids: regulation by protein phosphorylation and Ca2+-
calmodulin. Biochemistry 1996, 35:14651-14658.
22. Bredt DS, Ferris CD, Snyder SH: Nitric oxide synthase regulatory
sites. J Biol Chem 1992, 267:10976-10981.
848 Current Biology, Vol 9 No 15
Figure 4
Regulation of eNOS by phosphorylation at Thr495 and Ser1177.
Metabolic stress (AMPK) or growth factor receptor (Akt) mediated
signal transduction pathways target eNOS. A number of protein
kinases including Akt, AMPK [4], PKC (B.J.M., K.I.M. and B.E.K.,
unpublished observations and [21]) and CaM-K-II [22] cause activation
or inhibition of eNOS as indicated by a plus or minus sign,
respectively, by phosphorylating Ser1177 or Thr495. Abbreviations:
Palm, palmitoylation; Myr, myristoylation; CaM, CaM-binding domain;
N, amino terminus; C, carboxyl terminus.
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S1Supplementary material
Figure S1
Ser1179 phosphorylation in BAECs. BAECs were serum-starved in
DME containing 0.1% FBS for 20 h before incubation with 50 ng/ml
IGF-1 for 15 min, with or without pretreatment for 30 min with 200 nM
wortmannin, or 20 nM rapamycin, as indicated. After experimental
treatment, cells were washed and harvested as described in Figure 3.
eNOS was isolated from extracts by ADP–Sepharose chromatography
as described in Figure 3b and the relative amounts of phosphorylated
Ser1179 were determined by immunoblot analysis as described in
Figure 2 and expressed as mean ± standard error (n = 4).
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Figure S3
Time course of eNOS activation. Serum-starved BAECs were treated
with 50 ng/ml VEGF or IGF-1 for the time periods indicated. eNOS
was isolated from the clarified lysates as described in Figure 3 and its
activity was determined as described in Figure 2.
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Figure S2
Effect of Akt-catalyzed phosphorylation on eNOS activity.
Phosphorylation assays and eNOS activity determination were carried
out as described in Figure 2. The eNOS activity is expressed as
percentage of the maximum achieved in either the presence or the
absence of Akt. The K0.5 values for added CaM are 90 nM and
130 nM, respectively.
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